Cydectin 10% Long Acting | agridirect.ie (2024)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance
Moxidectin 100 mg

Excipeints
Benzyl Alcohol (E1519) 70 mg
For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Solution for injection.
Clear yellow liquid.

4 CLINICAL PARTICULARS
4.1 Target Species
Cattle.

4.2 Indications for use, specifying the target species

: .
Haemonchus placei .
Haemonchus contortus .
Ostertagia ostertagi (including inhibited larvae) .
Trichostrongylus axei .
Trichostrongylus colubriformis .
Nematodirus helvetianus (adults only) .
Nematodirus spathiger .
Cooperia surnabada .
Cooperia oncophora .
Cooperia pectinata .
Cooperia punctata .
Oesophagostomum radiatum .
Bunostomum phlebotomum (adults only) .
Chabertia ovina (adults only) .
Trichuris spp. (adults only)

.
Dictyocaulus viviparus

Hypoderma bovis .
Hypoderma lineatum

Linognathus vituli .
Haematopinus eurysternus .
Solenopotes capillatus . B
ovicolabovis (aid in control)

.
Sarcoptes scabiei .
Psoroptes ovis .
Chorioptes bovis (aid in control)

The drug has a persistent action and protects cattle for a certain duration against infection or re-infection with the following parasites for the period indicated:

Dictyocaulus viviparus 120
Ostertagia ostertagi 120
Haemonchus placei 90
Oesophagostomum radiatum 150
Trichostrongylus axei 90
Linognathus vituli 133

The product is effective against Hypodermalarvae at the time of treatment but its persistent activity against Hypodermahas not been evaluated.
If the product is given before the end of the fly season complimentary treatment with a product effective against Hypoderma may be required.
Persistent efficacy periods have not been established for parasite species other than those included in the above list. Therefore, re-infection of animals on pasturecontaminated by parasites other than these remains possible before the end of the 90 day minimum persistency period demonstrated for specific species.

4.3 Contraindications
Do not use in animals less than 100 kg bodyweight or greater than 500 kg.
Do not inject the product by intravascular route.
Intravascular injection may result in ataxia, paralysis, convulsions, collapse and death.
To prevent any intravascular injection, carefully follow the administration procedure described in item “Amounts to be administered and administration route”.

4.4 Special warnings for each target species
Care should be taken to avoid the following practices, because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time;
- Under-dosing which may due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (If any).
- Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test).
Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

4.5 Special precautions for use
Specialprecautionsforuseinanimals
In order to prevent abscesses, a strict aseptic technique is recommended.
CYDECTIN 10% LA for Cattle has been formulated specifically for subcutaneous injection in dorsal surface of the ear of cattle and must not be given by any other route of administration or to any other species.
To avoid possible secondary reactions by the death of Hypodermalarvae in the spine or the oesophagus of animals, it is recommended to administer a product effective against Hypodermalarvae after the end of fly activity and before the larvae reach their resting sites.
Consult your veterinary surgeon on the correct timing of this treatment.
Immunity to nematodes depends on adequate exposure to infection.
Although not normally the case, circ*mstances could occur in which anthelmintic control measures might increase the vulnerability of cattle to re-infection.
Animals may be at risk towards the end of their first grazing season, particularly if the season is long, or in the following year if they move onto heavily contaminated pasture.
In such instances, further control measures may be necessary.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal producttoanimals Avoid direct contact with skin and eyes.
Wash hands after use.
Do not smoke, drink or eat while handling the product.
Take care to avoid self-injection.

Advice to Medical Practitioners in case of accidental self injection:
Treat symptomatically.

Otherprecautionsregardingimpactontheenvironment
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance; therefore, exposure of the environment to moxidectin must be limited to the extent possible.
Treatments should be administered only when necessary and should be based on faecal egg counts or evaluation of the risk of infestation at the animal and/or herd level.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms:
 Faeces containing moxidectin excreted onto pasture by treated animals may temporarily reduce the abundance of dung feeding organisms.

Following treatment of cattle with the product, levels of moxidectin that are potentially toxic to dung fly species may be excreted over a period more than 4 weeks and may decrease dung fly abundance during that period.
It has been established in laboratory tests that moxidectin may temporarily affect dung beetle reproduction; however, field studies indicate no long-term effects.
Nevertheless, in case of repeated treatments with moxidectin (as with products of the same anthelmintic class) it is advisable not to treat animals every time on the same pasture to allow dung fauna populations to recover.

 Moxidectin is inherently toxic to aquatic organisms including fish.
The product should be used only according to the label instructions. Based on the excretion profile of moxidectin when administered as the injectable formulation, treated animals should not have access to watercourses during the 10 days after treatment.

4.6 Adverse reactions (frequency and seriousness)
On rare occasions, immediate or delayed swelling can be observed at the injection site, these swellings may further develop into abscesses (approx. 1% of cases).
The frequency of injection site swellings tends to be higher in the heavier animals.
These side effects generally disappear without treatment, within 14 days after administration, some may persist for up to 5 weeks in a number of animals (<5%) and in very rare occasions longer.
On rare occasions, depression and ataxia can be observed after injection.
In case of hypersensitivity reactions, a symptomatic treatment should be applied.

The frequency of adverse reactions is defined using the following convention:
-very common (more than 1 in 10 animals displaying adverse reaction(s))
-common (more than 1 but less than 10 animals in 100 animals treated)
-uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-rare (more than 1 but less than 10 animals in 10,000 animals treated)
-very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy. However, note 4.3. Contra-Indications.

4.8 Interaction with other medicinal products and other forms of interactions
The effects of GABA agonists are increased by moxidectin.

4.9 Amounts to be administered and administration route
Dosage is 0.5 ml/50 kg bodyweight, equivalent to 1.0 mg moxidectin/kg bodyweight, given by a single subcutaneous injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle.
The 50ml vial stoppers must not be broached more than 20 times.
Use automatic syringe equipment for the 200 ml vial.
Shake well before use.
To ensure administration of a correct dosage, body weight should be determined as accurately as possible; accuracy of the dosing should be checked.
The injection should be given subcutaneously in the loose tissues on the dorsal surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and allowed to briefly air dry.
Palpate the edge of the auricular cartilage closest to the head, on the dorsal (hairy) surface of the ear.
From this landmark, taking care to avoid blood vessels (artery, vein), the needle should be inserted subcutaneously starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head), and directed towards the base of the ear, and the needle advanced to the hub.
At this point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach worms, Ostertagia ostertagi and Haemonchus placei, a single treatment with theformulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic gastro-enteritis throughout the grazing season by reducing the build-up of infective larvae on pasture associated with these parasites.
For best results the injection should be given to each calf of target weight to be grazed together immediately prior to being turned out to pasture.
Animals should be set stocked throughout the grazing season or moved to a pasture which has not been grazed by other cattle earlier in the season.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Reactions at the injection site have to be expected more frequently and severe depending on the injected volume. Systemic signs of overdoses are consistent with the mode of action of moxidectin.
These signs are manifested as transient salivation, depression, drowsiness and ataxia 24 to 36 hours post-treatment. The systemic signs usually disappear within 36 to 72 hours without treatment.
At doses >3 times the recommended dose divided on both ears, the systemic signs included recumbency, muscle tremor, ruminal tympany and dehydration, which were resolved after treatment with fluids.
The systemic signs can last for a few days to ten days.
There is no specific antidote.

4.11 Withdrawal period(s)

108 days.

: Not permitted for use in lactating animals producing milk for human consumption or industrial purposes or within 80 days of expected parturition.
The withdrawal period is based solely on a single injection at the ear site of injection.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES
ATCvet Code
QP 54 AB 02

Pharmacotherapeutic group:
Endectocides

5.1 Pharmacodynamic properties
Moxidectin is an endectocide active against a wide range of internal and external parasites and is a second generation macrocyclic lactone of the milbemycin family.
Moxidectin interacts with GABA receptors and chloride channels.
The net effect is to open the chloride channels on the postsynaptic junction to allow the inflow of chloride ions and induce an irreversible resting state.
This results in flaccid paralysis and eventual death of parasites exposed to the drug.

5.2 Pharmaco*kinetic particulars
Moxidectin is absorbed following subcutaneous injection with maximum blood concentrations being achieved 24 to 48 hours post injection.
The drug is distributed throughout the body tissues but due to its lipophilicity it is concentrated mainly in the fat.
The depletion half life in fat is 26 – 32 days.
Moxidectin undergoes limited biotransformation by hydroxylation in the body.
The only significant route of excretion is the faeces.

5.3 Environmental properties
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance. In particular, in acute and chronic toxicity studies with algae, crustaceans and fish, moxidectin showed toxicity to these organisms, yielding the following endpoints:

S. capricornutum >86.9 μg/l 86.9 μg/l

Daphnia magna (acute) 0.0302 μg/l 0.011 μg/l
Daphnia magna (reproduction) 0.0031 μg/l 0.010 μg/l
Fish O. mykiss 0.160 μg/l Not determined
L. macrochirus 0.620 μg/l 0.52 μg/l
P. promelas (early life stages) Not applicable 0.0032 μg/l
Cyprinus carpio 0.11 μg/l Not determined

EC50: the concentration which results in 50% of the test species individuals being adversely affected, i.e. both mortality and sub-lethal effects.
NOEC: the concentration in the study at which no effects are observed.
This implies that when allowing moxidectin to enter water bodies, this may have a severe and lasting impact on aquatic life. To mitigate this risk, all precautions for use and disposal must be adhered to.

6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Benzyl alcohol (E1519)
Sorbitan Monooleate (Crill 4HP)
Propylene Glycol
Dicaprylate/Dicaprate

6.2 Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.